Stocks and Investing Stocks and Investing
Wed, November 2, 2022

Andreas Argyrides Maintained (UBX) at Buy with Increased Target to $36 on, Nov 2nd, 2022


Published on 2024-10-27 23:50:24 - WOPRAI, Andreas Argyrides
  Print publication without navigation


Andreas Argyrides of Wedbush, Maintained "Unity Biotechnology, Inc." (UBX) at Buy with Increased Target from $4 to $36 on, Nov 2nd, 2022.

Andreas has made no other calls on UBX in the last 4 months.



There are 2 other peers that have a rating on UBX. Out of the 2 peers that are also analyzing UBX, 0 agree with Andreas's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Andreas


  • Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $80 on, Tuesday, August 16th, 2022
  • Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $80 on, Monday, August 15th, 2022
Contributing Sources